Rapid and point-of-care testing in respiratory tract infections: An antibiotic guardian? by Dhesi, Zaneeta et al.
TITLE  
Rapid and Point of Care Testing (POCT) in Respiratory Tract Infections: An Antibiotic Guardian? 
AUTHORS 




1University College London, Gower Street, London WC1E 6BT   
2Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UA 
3University College London Hospitals NHS Foundation Trust, London, NW1 2PG    
4University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ   
RUNNING HEAD 
Detecting antibiotic resistance in bacterial respiratory infection   
KEYWORDS/ KEY CONCEPTS 
Point of care testing (POCT)/ Antimicrobial resistance / Pneumonia/ Rapid molecular diagnostics / 
Biomarkers / Next generation sequencing.   
We present a review of the potential for rapid diagnostics, based in either the laboratory- or at point 
of care, to improve clinicians’ antibiotic prescribing decisions. We describe the current state of 
available technologies and discuss their potential to support antibiotic stewardship. 
CORRESPONDING AUTHOR AND CONTACT DETAILS 
Dr. Zaneeta Dhesi  
Email address: z.dhesi@ucl.ac.uk  
Postal address: Dept. for Clinical Microbiology, 2nd Floor Royal Free Hospital, University College 



















This is a narrative review on the potential of rapid and point-of-care microbiological testing in 
pneumonia patients, focusing particularly on hospital-acquired and ventilator-associated pneumonia, 
which have substantial mortality and diverse microbiology. It is written from a UK perspective, but 
much is generalizable internationally. In a world where antimicrobial resistance is a major 
international threat, the use of rapid molecular diagnostics has great potential to improve both the 
management of pneumonia patients and the stewardship of antibiotics. Rapid tests potentially can 
distinguish patients with bacterial versus viral infection and can swiftly identify bacterial pathogens 
and their resistances.  
We seek to answer the question: ‘Can such tests be used as an antibiotic guardian?’  Their 
availability at the bedside rather than in the laboratory should best ensure that results are swiftly used 
to optimize patient management, but will raise new challenges, not least in respect of maintaining 
quality control and microbiology/infection control input.  A further challenge lies in assessing the 
degree of trust that treating clinicians will place in these molecular diagnostic tests, particularly when 
early de-escalation of antibiotic therapy is indicated.   
  
INTRODUCTION  
Antimicrobial resistance (AMR) is a major public health issue, increasing morbidity and mortality, as 
illustrated by population-level modelling across Europe.1  Numerous governmental and agency reports 
assert that the best routes to managing this growing challenge lie in: (i) better infection control, 
minimizing the need to use antibiotics, (ii) reinvigorating antibiotic discovery and development, and 
(iii) better ‘stewardship’ of available antibiotics, meaning swift administration of the ‘right antibiotic 
at the right dose for the right duration’ for those patients with a significant bacterial infection, whilst 
ensuring that antibiotics are not given to patients with viral infections, who will not benefit from them. 
Unfortunately, stewardship is complicated by the fact that most initial antibiotic use is empiric, with 
the physician not knowing the identity or antibiotic resistances of the pathogen – if one is grown at all 
– until 2-3 days into therapy.  In countries with moderate rates of resistance, including the USA and 
much of Europe, this leads to precautionary over-treatment, with broad-spectrum antibiotics given to 
patients who transpire to have not-very-resistant pathogens, or not to have bacterial infections. In 
countries with high rates of resistance and particularly where carbapenemase-producing gram-
negative bacteria are prevalent (as e.g. in India), the delay in pathogen identification leads to forced 
empiric use of less effective and potentially toxic agents, notably colistin combinations.  In some cases, 
even these fail to cover the pathogen(s) ultimately grown.  
It is widely agreed (and reflected e.g. in the UK Government’s 5-year action plan on AMR 2) 
that this undesirable situation could be improved by deploying rapid diagnostics to better discriminate 
between bacterial and viral infection, and/or to deliver accelerated profiling of bacterial pathogens 
and their resistances. Such information should drive much better antibiotic stewardship, promoting 
early use of narrow-spectrum agents targeted against the particular pathogen(s) present, instead of 
the current model, where – until microbiology results become available – guidelines favor broad-
spectrum agents chosen to cover all pathogens likely to be present, based on epidemiological 
surveillance data.   Rapid results should also prompt termination of antibacterial therapy in patients 
found to have viral infections.  Ideally a ‘rapid’ diagnostic should give an immediate result; in practical 
terms, a result within one dosage interval (typically 8h) for an initially-given empiric antibiotic seems 
a good target, allowing early refinement of therapy. 
This review focuses on the potential utility of rapid molecular and point-of-care testing (POCT) 
diagnostics in patients with respiratory infection, particularly those admitted to hospital with 
community-acquired pneumonia (CAP) and those who, during their stay, develop hospital-acquired or 
ventilator-associated pneumonia (HAP and VAP, respectively).  It is written from a UK perspective, but 
the content is internationally relevant, since the pathogens of pneumonia are largely identical 
worldwide, though resistance rates and healthcare delivery systems vary by country.  
Severe pneumonia has high mortality and is a common cause of admission to an intensive care 
unit (ICU), with the current situation complicated by the COVID-19 pandemic.  Empirical broad-
spectrum antibiotics are ordinarily used to treat pneumonia and are often continued for prolonged 
periods even when no bacterial  pathogen is cultured.3     
In normal (i.e. pre-COVID-19) times it was estimated that 0.5% -1% of UK adults would develop 
CAP in a given year4; moreover pneumonia is diagnosed in 5–12% of adults who present to General 
Practitioners (GPs) with symptoms of lower respiratory tract infection (LRTI).  Around 22–42% of these 
CAP patients are admitted to hospital, where their mortality rate is between 5% and 14%.4  Between 
1.2% and 10% of adults admitted to hospital with CAP are managed in intensive care, and, among 
these, mortality exceeds 30%.4   In addition, debilitated patients commonly develop pneumonia whilst 
in hospital and this risk increases with mechanical ventilation, where tubing and liquid traps become 
colonized by bacteria that then reach the lungs.  HAP (even excluding VAP) is estimated by the UK’s 
National Institute of Clinical Excellence (NICE) to increase a hospital stay by 8 days on average and has 
a reported mortality between 30 to 70%, ‘with variations in clinical management and outcomes across 
the UK’.4  In our experience, such rates are for severe pneumonia and not for the many ‘HAP’ patients 
‘Who have a few crackles’.  
Current practice, for a patient with clinically suspected pneumonia (regardless of type), is to 
take a sputum or endotracheal aspirate sample (ETA), send it to the microbiology laboratory for 
culture, and to start empirical antibiotics in line with the hospital’s local antibiotic prescribing policy, 
which generally reflect national guidelines (Fig.1).  These sample types are easy to take but are prone 
to become contaminated with upper respiratory tract flora, leading to uncertainty about whether the 






Bronchoalveolar lavage (BAL), delivers a deep-lung specimen, and is widely performed in some 
countries such as France and the US, but is rarely done in the UK, being seen as invasive and carrying 
some risk.5 Imaging findings, oxygen requirements and inflammatory markers all contribute to the 
clinical differential diagnosis.  Cultures, with susceptibility tests on relevant pathogens, take 2 to 3 
days, and the processing, interpretation and reporting of these results varies among laboratories.  
Adopting the model – long established in e.g. Germany and increasingly seen in the UK – whereby a 
few centralized laboratories serve multiple hospitals enhances test standardization and quality 
control, but may delay sample processing for remote sites.   Moreover, even in clinical trials, only 
around 30-40% of CAP patients have a pathogen grown; in routine practice the proportion with a clear 
microbiological diagnosis was only 28.5%.6  Major factors here are: (i) that common CAP pathogens, 
notably Streptococcus pneumoniae and Haemophilus influenzae are difficult to culture, leading to low 
recovery rates and (ii) that, when scanty or mixed opportunist organisms are grown from HAP and 
VAP patients, as is common with sputa and ETA samples, the microbiologist must make a subjective 
judgement of their significance.   What is more, HAP and VAP are difficult to diagnose clinically in 
patients with multiple other pathologies.7   These multiple diagnostic uncertainties are reflected (i) in 
variations in treatment duration, (ii) in patients receiving repeated courses of antibiotics for vague 
ongoing symptoms thought to be due to a pneumonia and (iii) in UK hospital guidelines advocating 
the antibiotic doxycycline in ‘mild HAP’ despite an inappropriate spectrum and a lack of national or 
international guideline support.8 For community respiratory infections, patient expectation plays a big 
role in inappropriate antimicrobial prescribing, as do the constraints put on GPs, including their ten-





ETIOLOGY OF PNEUMONIA 
Bacterial CAP is usually attributable to a narrow range of pathogens, principally S. pneumoniae, H. 
influenzae, Moraxella catarrhalis, Legionella pneumophila, and the ‘atypicals’, collectively including 
Chlamydophila pneumoniae and Mycoplasma pneumoniae.   
 The opportunistically pathogenic agents of HAP and VAP are more diverse: Enterobacterales, 
Pseudomonas aeruginosa and Staphylococcus aureus are all prominent globally, each accounting for 
around a quarter to a third of cases.10 The importance of other pathogens in HAP/VAP varies 
geographically. This is particularly the case for Acinetobacter baumannii, which is widely listed among 
the most important ICU-VAP pathogens in East and South Asia as well as Latin America11, 12 but is 
uncommon e.g. in the UK.  It is unclear whether this variation reflects: (i) the effectiveness of infection 
control, (ii) climatic factors, with A. baumannii thriving in warmer and moister conditions, (iii) 
antibiotic pressure, or (iv) differing patient populations, particularly in respect of admission of 
terminally-ill (and very-Acinetobacter-vulnerable) patients to ICU.  Although single Gram-negative and 
positive bacteria are often responsible for HAP and VAP, Girard et al. 13 described 276/946 (29.2%) 
VAPs as polymicrobial.  
  Gram-negative bacteria are increasingly multi-drug resistant in many countries, driving the 
sort of polypharmacy indicated e.g. in Infectious Disease Society of America (IDSA) guidelines.14 These 
advocate that, if a unit has an MRSA rate >10-20% and >10% resistance to anti-Gram-negative agents 
(conditions that apply at virtually all ICUs across much of Asia or Latin America as well as many in 
Europe and the USA), then empiric therapy for HAP/VAP should comprise two antipseudomonal 
agents plus an anti-staphylococcal active against MRSA.  Whilst this approach covers likely pathogens 
it can hardly be seen as ‘stewarding’ antibiotics or minimizing undesirable side effects, including 
disruption of the gut flora – which may allow proliferation of resistant organisms and/or Clostridium 
difficile.  In settings with extreme rates of resistance even colistin comes to be considered as a 
component of empirical treatment for pneumonia, despite significant toxicity and questionable 
pharmacodynamics in the lung.15 
 Important resistance mechanisms among the bacterial pathogens of pneumonia are 
summarized in Table 1.  This table also highlights the diversity of these mechanisms within species 
groups and whether resistance largely involves acquired genes carried by plasmids or transposons or 
is largely attributable to chromosomal mutations.  These aspects become critically important when 
seeking to predict resistance phenotypes from molecular data generated in the types of tests outlined 
below.  It is far easier to use a molecular method to predict oxacillin resistance in staphylococci – 
almost always attributable to acquired mecA – than it is to predict oxyimino-cephalosporin resistance 
in e.g. Klebsiella pneumoniae, where the possible determinants include a wide range of different -
lactamase genes, some of them point mutants of genes that determine -lactamases unable to attack 
these cephalosporins. 
Table 1.  Frequency and genetic diversity of critical modes of resistance: implications for the development of rapid genetic tests. 
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Green: Resistance almost always due to 1 or 2 acquired genes which could be easily sought by molecular tests 
Blue: resistance mechanisms well conserved, but mutational, making them difficult to seek without sequencing 
Yellow: Resistance almost always due to one of 6 or fewer acquired genes: good scope to seek by PCR tests 
Pink: Resistance mechanisms highly diverse. This may because many different acquired enzymes can be involved, as with the multiplicity of different  
penicillin- and cephalosporin- hydrolysing -lactamases that occur in Enterobacterales 16 or because, although a  biochemical or biophysical mechanism is 
well conserved, its genetic underpinnings are variable.  Thus, for example, many different mutations can disrupt porin OprD in P. aeruginosa, all leading to 
impermeability to carbapenems.17  PCR based prediction of such a resistance is difficult or impossible, though both sequencing and rapid phenotypic tests 
remain viable approaches.   
Grey: diversity of mechanisms (at the genetic level) uncertain 
White: inherent resistance, predictable for the species/genus identification 
  
The prevalence of resistance varies hugely among countries. In the UK, around 13% of K. 
pneumoniae isolated from LRTIs have extended-spectrum -lactamases (ESBLs), conferring resistance 
to oxyimino-cephalosporins and around 0.9% have carbapenemases (according to BSAC surveillance 
data, http://www.bsacsurv.org). In India these proportions rise to 86.9% and 56.6%, respectively.18  
The relative prevalence of particular mechanisms also varies geographically; thus KPC enzyme is the 
predominant carbapenemase of Enterobacterales in the Americas, China, Italy, Israel, Greece and 
Portugal but OXA-48 enzyme dominates elsewhere in Europe and in the Middle East, whilst NDM is 
the major carbapenemase among Enterobacterales in the Indian subcontinent.19  As a second 
example, most resistance to -lactams in P. aeruginosa is mutational in Europe and the US, whereas 
large proportions of resistant Pseudomonas in the Middle East have acquired ESBLs or 
carbapenemases.20, 21  
In summary, the slowness and poor pathogen-recovery rates of conventional microbiology 
impacts clinical decision-making and, in particular, delays the stopping or narrowing antibiotic therapy 
for the many patients with susceptible pathogens. Equally, it delays the initiation of active therapy for 
those patients with particularly resistant pathogens, delaying cures, increasing mortality, prolonging 
hospital stay, and adding to costs.22, 23  Presently, there is no reliable tool to facilitate swift refinement 
of the patient’s empirical antibiotics.  Such tests would play the part of an invaluable antibiotic 
guardian but face the challenge of having to seek multiple pathogens and, in some cases, a great 
diversity of resistance mechanisms. 
   
POINT OF CARE TESTING – WHAT’S THE POINT?  
Rapid diagnostics potentially could improve both the care of the pneumonia patient and antibiotic 
stewardship.24, 25  Potentially useful types of test, in context, include those to: (i) measure 
inflammatory markers to better distinguish bacterial versus viral pneumonia; (ii) seek specific 
respiratory viruses such as influenza, (iii) seek broad arrays of bacteria, viruses and resistance genes, 
(iv) detect atypical bacteria, meaning those that cannot readily be grown in the laboratory, and (v) 
detect urinary antigens specific for Legionella and pneumococci.    
To be most useful a rapid method needs to be deployed as a Point of Care Test (POCT), 
providing a result at the hospital patient’s bedside or in the GP surgery.  Bedside tests eliminate the 
transport delay to the laboratory, accelerating decisions about patient management, although they 
also introduce challenges of their own, discussed later in this article.   Sexual Health Services have 
been using POCTs several years, and these are highly valued among their patients.26   
 
POCT OF INFLAMMATORY MARKERS, TO DISTINGUISH VIRAL AND BACTERIAL INFECTION  
C-Reactive Protein (CRP) is an acute phase protein expressed in response to infection or inflammation.  
CRP tests can be used for the differential diagnosis of bacterial and viral respiratory infections in the 
community, albeit mostly for less serious conditions than pneumonia.   Such tests are widely employed 
by GPs in Scandinavia and the Netherlands, partly because of their direct value in identifying patients 
likely to benefit from antibiotics, but also because a negative result provides objective justification to 
deny unnecessary antibiotics to a demanding patient.27   
 A randomized cluster study including 20 general practices in the Netherlands showed that 
deployment of a CRP POCT testing significantly reduced antibiotic prescribing in LRTI, without 
compromising care.28  A large trial, involving 25,497 Spanish patients, demonstrated that CRP testing 
was useful in reducing prescriptions to GP patients who specifically asked for antibiotics.29  A UK study 
suggested a financial benefit to using CRP tests in the community, though these may be hard to 
achieve given the low acquisition cost of generic antibiotics. 30 A review concluded that CRP tests could 
aid appropriate antibiotic prescriptions as well as being cost effective.27  In the UK, NICE guidelines 
advocate the use of CRP tests in primary care to reduce antibiotic use, suggesting prescribing 
antibiotics only if the CRP is above 100 mg/L.4  This view may (or may not) be supported by the ongoing 
PACE randomized control trial, using CRP tests to target antibiotic prescribing in community patients 
with acute exacerbations of chronic pulmonary disease.31   
Procalcitonin, a peptide precursor of the hormone calcitonin, has been the subject of much 
debate as an indicator of bacterial infection, and there is evidence to suggest its use as an adjunctive 
tool for antimicrobial stewardship.32  Briefly, procalcitonin concentrations  are raised in bacterial 
pneumonia, but can also be elevated owing e.g. to chronic kidney disease, malignancies, burns, 
trauma, and by some immune-modulating drugs.  One UK-based study used procalcitonin testing in 
99 acute medical and 42 ICU patients who were thought to have an infection, denying antibiotics if 
concentrations  were low.  This approach led to a reduction in antimicrobial use, with no infection-
related deaths.33  A Swiss trial used procalcitonin tests in patients admitted with CAP, randomizing 
them to a standard care arm or to one where antibiotic use was guided by procalcitonin 
concentrations.34  A total of 302 patients were recruited and the duration of antibiotic therapy was 
reduced from a median of 12 days in the standard care arm to 5 days in procalcitonin arm (55% 
reduction; p < 0.001).   
Based on positive data, such as these, a one-day meeting between 19 experts from 12 
countries (funded by ThermoFisher Scientific, as a test manufacturer)35 configured three algorithms 
(Table 2) to guide the use of procalcitonin with the aim of aiding antimicrobial stewardship, based on 
interventional trials.  Clinical assessment, radiographic assessment, and microbiological work-up were 
used to assess the probability of bacterial infection.    
 
  
TABLE 2: ALGORITHMS DEVELOPED FOR PROCALCITONIN USE.35 
 Bacterial infection 
uncertain and PCT 
below threshold  
Bacterial infection 
uncertain and PCT 
at or above 
threshold  
Bacterial infection 
highly suspected and 
PCT below threshold  
Bacterial infection 
highly suspected and 
PCT at or above 
threshold  
Patient with mild 
illness outside ICU; PCT 
threshold 0.25 ng/ml 
Bacterial infection 
unlikely. Withhold 
Abx1, consider other 
diagnostic tests to 
establish diagnosis 
Bacterial infection 
likely. Use Abx 




Use empiric Abx 
based on clinical 
judgement, consider 
other diagnostic tests 
Bacterial infection 
highly likely. Use Abx 
based on clinical 
judgement 
Patient with moderate 
illness outside ICU; PCT 
threshold 0.25 ng/ml 
Bacterial infection 
unlikely. Use empiric 
Abx based on clinical 
judgement, consider 
other diagnostic tests 
Bacterial infection 
likely. Use Abx 
based on clinical 
judgement 
Bacterial infection 
possible. Use empiric 
Abx based on clinical 
judgement, consider 
other diagnostic tests 
Bacterial infection 
highly likely. Use Abx 
based on clinical 
judgement 
Patient with severe 
illness in ICU; PCT 
threshold 0.5 ng/mL 
Bacterial infection 
unlikely. Use empiric 
Abx based on clinical 
judgement, consider 
other diagnostic tests 
Bacterial infection 
likely. Use Abx 
based on clinical 
judgement 
Bacterial infection 
possible. Use empiric 
Abx based on clinical 
judgement, consider 
other diagnostic tests 
Bacterial infection 
highly likely. Use Abx 




Other analyses are less positive.  A meta-analysis, which included 12 studies on the use of 
procalcitonin testing in patients with CAP, 36 concluded that it was an unreliable test when deciding 
whether or not to initiate antibiotics – finding a pooled sensitivity of 0.55, and specificity of 0.76.  
Similarly, the UK’s NICE concluded that more evidence is needed with respect to using procalcitonin 
data to support stopping antibiotic treatment in ICU cases with confirmed or strongly suspected 
sepsis, and or starting and stopping antibiotic treatment in people with suspected bacterial infection 
presenting to the emergency department.37    
One possible refinement is to monitor changes in procalcitonin over time rather than 
obtaining a single ‘snapshot’ reading.  On this basis, the multicenter PRORATA RCT 38, undertaken in 
France and Germany, monitored procalcitonin concentrations daily for patients on antibiotics; and at 
each infectious episode, until day 28.  It recruited 307 patients to the procalcitonin-guided group and 
314 to a control group, given empirical antibiotics according to guidelines.  Patients in 
the procalcitonin group had significantly more antibiotic-free days (out of the 28) than those in the 
control group - 14.3 days vs 11.6 days; 95% CI 1.4 to 4.1, p<0.0001.  However, an observational study 
on an ICU in Israel concluded that serial early procalcitonin measurements (at 0, 6, 12 h) were of no 
more use than a single initial value. 39   
Other biomarkers may have potential to guide antimicrobial stewardship, besides CRP and 
procalcitonin, but have been studied less extensively.   Hellyer et al. undertook the VAPrapid-2 study, 
where BAL samples were tested for IL-8 and IL-1β 40 as markers for VAP, which was defined as growth 
of >10⁴ colony forming units (CFU) per mL of BAL fluid.  Initial observational work showed that 
combined measurement of IL-1β and IL-8 could be configured to exclude VAP with a sensitivity of 
100%, a specificity of 44.3% and a negative predictive value  (NPV) of 1, making it a good ‘rule out’ 
test.  A subsequent RCT, with 104 patients randomized to the biomarker-guided recommendation on 
antibiotics and 106 randomized to routine use of antibiotics, found no significant difference in days of 
antibiotic treatment in the week following BAL in the intention-to-treat analysis (p=0·58). The authors 
attributed this failure to local prescribing culture/habits and to the fact that testing was laboratory-
based, not as a POCT, extending turnaround time and precluding immediate impact on the treating 
physicians.40, 41  Horonenko et al. 42 assayed Soluble Triggering Receptor (sTREM-1, a receptor 
expressed on myeloid cell-1), in BAL fluid and exhaled ventilator condensate as a possible predictor of 
VAP, which they defined using a clinical pulmonary infection scoring system.43 Results were promising, 
although numbers are small, with sTREM-1 detected in the condensate from 11 of 14 subjects with 
VAP, but from only 1 of 9 subjects without infection.42   
Future diagnostic prospects, presently in their infancy, include using large batteries of host 
transcriptome biomarkers.  One panel suggested to be of value in pneumonia - the HostDx Sepsis test 
-has been developed by Inflammatix in the USA.44  This uses a blood sample from the patient to identify 
the presence, type (bacterial/viral), and severity of an acute infection in 30 mins.  It seeks 29-mRNAs, 
produced by white cells in peripheral blood, that may have their expression modulated by infection.  
Likelihood ratios are calculated using proprietary bioinformatics data at Inflammatix’ laboratory.  
Specific details of the gene set have not been released and the test requires clinical evaluation.  For a 
wider review of biomarkers in sepsis, rather than pneumonia,  readers are referred to Teggert et al.45  
 
RAPID METHODS TO SEEK RESPIRATORY VIRUSES AND ‘ATYPICAL’ BACTERIA  
To date, both pre-COVID-19 and currently, rapid microbiological PCR-based diagnostics, mostly run in 
the laboratory rather than as POCTs, have been more used to seek respiratory viruses than bacterial 
pathogens, typically among emergency admissions with respiratory symptomology.  Their wide 
adoption in this role is partly because detection of a pathogenic virus, which should not be present in 
a healthy patient, gives a clear diagnosis whereas detection of a low burden of, for example, 
Acinetobacter  in a ventilated ICU patient does not. Moreover, classical virology, unlike classical 
bacteriology, is complex and costly.    These systems also potentially allow for the rapid detection of 
patients with high consequence infections, including Middle East respiratory syndrome (MERS) 
coronavirus, essential for patient management/infection control purposes.   If a virus is found, it may 
prompt specific antiviral therapy, particularly in the case of influenza. Moreover, finding a pathogenic 
virus, including SARS-CoV2, should discourage the use of broad-spectrum antibacterials, though 
narrower-spectrum coverage against likely secondary pathogens (e.g. S. aureus and S. pneumoniae 
following influenza) may be preferred.   
Available systems, and the pathogens they seek are tabulated in Table 3; it should be assumed 
that all manufacturers are adjusting panels to include SARS-CoV2.  Some include difficult-to-grow 
bacteria as well as viruses, notably including the agents of atypical pneumonia.  Some (e.g. the BioFire 
FilmArray) can also run different PCR panels, suited to seeking wider ranges of bacteria, including 
agents of HAP and VAP. There are also many specific POCTs for influenza; these are beyond the scope 
of this article, readers are directed to Egilmezer46 for a detailed review.   
 
TABLE 3 – Respiratory Molecular Panels: Organisms and resistance genes sought  
Manufacturer Curetis Unyvero BioFire FilmArray Nanosphere Hologic  Seegene 
























NPS NPS  NPS 
NP aspirate 
BAL 
Sputum   
Viruses         
Adenovirus    x x  x x 
Coronavirus    x x   x 
Human 
Metapneumovirus 
   x x  x x 
Human Rhinovirus/ 
Enterovirus 
   x x   X 
Influenza A    x x X x X 
Influenza B    x x X x X 
Parainfluenza Virus    x x  x X 
Respiratory 
Syncytial Virus 
   x x x x X 
Human Bocavirus        X 
MERS Co-V      X (only on the 
Pneumonia 
Plus Panel) 
   





x x x  x    
Stenotrophomonas 
maltophilia 
x x x      
Enterobacter 
cloacae complex 
 x x  x    
Enterobacter spp. x        
Escherichia coli x x x  x    
Haemophilus 
influenzae 
x x x  x   x 
Klebsiella 
aerogenes 
 x   x    
Klebsiella oxytoca x x x  x    
Klebsiella 
pneumoniae  
x x x  x    
Klebsiella variicola  x x      
Moraxella 
catarrhalis, 
    x    
Proteus spp. x x x  x    
Morganella 
morganii 
x x x      
Citrobacter freundii  x x      
Moraxella 
catarrhalis 
x x x      
Pseudomonas 
aeruginosa 
x x x  x    
Serratia marcescens x x x  x    
Staphylococcus 
aureus 
x x x  x    
Streptococcus 
agalactiae 
    x    
Streptococcus 
pneumoniae 
 x x  x   x 
Streptococcus 
pyogenes 
    x    
Streptococcus mitis 
group  
x        
Chlamydophila 
pneumoniae 
x x x x x   x 
Legionella 
pneumophila 
x x x  x   x 
Mycoplasma 
pneumoniae 
 x x x x   x 
Bordetella 
parapertussis 
   x    x 
Bordetella pertussis    x    x 
Fungi         
Pneumocystis 
jirovecii 
x x x      
Resistance genes         
ermA x        
ermB x x       
ermC x        
msrA x        
mefA/E x        
mecA x x x  x    
mecC  x   x    
blaTEM x x x      
blaSHV  x x       
blaCTX-M  x x x  x    
blaEBC x        
blaDHA  x        
blaKPC  x x x  x    
blaIMP   x   x    
blaNDM   x x  x    
blaVIM   x x  x    
blaOXA-23   x x      
blaOXA24/40   x x      
blaOXA-48   x x  x    
blaOXA-58  x x      
blaOXA 51 like  x        
int1 x        
sul1 x x       
gyrA83 x x       
gyrA87 x x       
parC x        
This table include the major tests which seek bacteria and viruses; other more specific tests are available, but are excluded. 
 
A systematic review by Huang et al. in 201847 considered performance of the FilmArray, 
Verigene RV+ and Prodesse for diagnosis of viral respiratory infections.   The authors included 20 
studies representing a total of 5510 upper and lower respiratory tract samples from children and 
adults, and variously comparing performance to virus culture, direct fluorescent antibody tests and to 
commercial and local ‘in-house’ real-time PCR (RT-PCR).  Viruses included were influenza A and 
B, respiratory syncytial virus, human metapneumovirus and adenovirus; parainfluenza was excluded 
due to lack of data.  The most promising results were for influenza A, where the platforms reviewed 
had a combined sensitivity of 0.940 (95% CI, 0.902–0.964) and high specificity 0.987 (95% CI, 0.979, 
0.992).  All platforms individually had an area under the receiver operating characteristic curve 
(AUROC) of 0.99.  For influenza B, the FilmArray performed slightly worse (sensitivity 0.822 (0.689, 
0.905), and AUROC 0.98) compared with the Prodesse (sensitivity 0.963, AUROC 0.99). Adenovirus 
was only sought by the FilmArray panel had the poorest diagnostic accuracy (AUROC 0.89).  The review 
concluded that these systems helped early diagnosis of viral respiratory infections.    
The BioFire FilmArray Respiratory Panel has been evaluated by multiple groups, including in 
RCTs against standard of care; results for this panel, which has been the most-evaluated, are 
summarized here and are likely to be generalizable across similar systems.  One UK-based RCT of this 
panel, ResPOC, (2017) enrolled 720 patients presenting  in Accident and Emergency (A&E) or the acute 
medical unit of a large UK teaching hospital with acute respiratory illness and/or a fever of >37.5oC.48, 
49  Patients were randomized to routine care or to testing using the FilmArray panel. In the latter case, 
research staff took a nose and throat swab and ran it immediately on the FilmArray.  Strikingly, 91% 
of patients (52/57) with confirmed influenza in the FilmArray group received appropriate antivirals, 
compared with 65% (24/37) of those diagnosed with influenza in the control group (p 0.0026).   In 
reality this differential was greater because, in the control arm, only patients with clinically suspected 
infection were tested with in-house laboratory PCR, as reflected in the low denominator for this group.  
The authors highlight that cases may well be missed if reliant upon clinical diagnosis based on a 
syndrome.  Patients in the FilmArray arm had a reduced length of stay: 5.7 days vs. 6.8 days for the 
control group (95% CI −2·2 to −0·3 days; p=0·0443), and more often had shorter or discontinued 
antibiotic courses (difference 7·8%, 95% CI 2·5 to 13·1; p=0·0047).  Reduced hospital stay in the 
FilmArray arm was due to earlier discharge of patients confirmed to have respiratory viruses.  
However, the proportion of patients treated with intravenous antibiotics and their average duration 
of antibiotic treatment (in days) did not differ between the two arms; moreover fully 301/360 (84%) 
patients in the POCT group received antibiotics during their admission compared with 294 /354 (83%) 
of 354 in the control group.   
 In Japan, Kitano et al. introduced the FilmArray to the management of pediatric patients with 
respiratory infections in March 2018. 50 Performance, using nasopharyngeal swabs from 149 patients 
over the subsequent year to April 2019, was compared with the use of rapid antigen tests in the same 
demographic (1132 patients) over the preceding 6 years from March 2012 to March 2018.  The 
average duration of antibiotic therapy fell from 12.82 to 8.56 days (p<0.001) and the length of stay 
from 8.18 to 6.83 days (p=0.032).    These results appear striking but are complicated by the historic 
control; it is unclear whether durations of hospitalization or antibiotic therapy were already falling 
during the years prior to implementation of the test, or whether its introduction resulted in a step 
change. 
An 800-patient RCT in China used the FilmArray with the Respiratory Panel for hospitalized 
cases with LRTI, 51 compared with routine real-time PCR assays in the hospital laboratory.  Courses of 
intravenous antibiotics were found to be shorter in the FilmArray group (7.0 days (interquartile 
range (IQR) 5.0-9.0) versus 8.0 days (IQR 6.0-11.0); p <0.001), as was the duration of hospital stay 
(8.0 days (IQR 7.0 -11.0) versus 9.0 days (IQR 7.0-12.0; p <0.001), which directly related to the 
duration of IV antibiotics.  Unlike Kitano’s study 50, above, this was a comparison of PCR techniques 
(as opposed to a control arm using rapid antigen tests or culture); nonetheless the median turn-
around time (including processing, running and reporting) in the FilmArray group was 1.6 h vs 29.0 h, 
(p < 0.001) in the control group.  Financial implications were analyzed, with less overall cost per 
patient when the FilmArray Panel was used ($1804.7 (IQR 1298.4-2633.8) versus $2042.5 (IQR 
1427.4-2926.2); p= 0.002).  These savings may not translate to other healthcare systems with 
different models to China; nonetheless, this study suggests that commercial real time PCR tests 
could play a part both in antimicrobial stewardship and in reducing hospitalization costs.   
In contrast to these broadly positive results from the UK, Japan and China, another UK hospital 
-based study, which used the FilmArray Respiratory Panel on 606 patients who presented with upper 
or lower respiratory tract infection or ‘influenza-like symptoms from January 2015- July 2015, found 
that, although antivirals were given a day and a half quicker in the intervention arm (p < 0.001), length 
of stay was not reduced compared with patients managed by routine laboratory respiratory PCR and 
serological testing. 52  The authors describe their study as a ‘quasi-randomized trial’, meaning that, on 
odd-numbered days of the month, patients were enrolled into the control arm, and on even-
numbered days into the intervention arm.  The machines were placed on two acute medical adult 
wards, and a medical assessment unit.  The authors account for their failure to reduce length of stay 
by remarking frequent delays in FilmArray testing, which often was performed only when the study 
investigators visited the wards.  This suggests a flaw in study design but underscores the point --- 
expanded below in ‘Practicalities of introducing molecular methods’– that any gain arising from rapid 
tests will only translate into practical advantage if the technology is close to the patient and if tests 
are performed without delays arising from the need for specialist personnel or from transport issues.   
 Three further studies merit comment.  First, a retrospective observational analysis by Li et al. 
53 reviewed patients presenting with viral respiratory tract infection at three A&E departments in 
California between October 2016 and March 2017.  Three hundred and twenty-three of 424 (76.2%) 
patients had a positive viral PCR result from a nasopharyngeal swab tested using the FilmArray 
Respiratory Panel available to the clinician before they were discharged from A&E; the remainder had 
results available post discharge.  Among the former 323 patients, only one-fifth were prescribed 
antibiotics – far fewer than would ordinarily be expected – underscoring the potential of this multiplex 
PCR as a stewardship tool.  Patients diagnosed with influenza by PCR were particularly unlikely to 
receive antibiotics. Antiviral prescribing was not reviewed. Multivariate analysis identified factors 
influencing the antibiotic prescribing decision, many related to concerns over secondary bacterial 
infection.  Decision-making is complex, and patients can have more than one pathology.  Secondly, a 
2017 study by Chen et al. 54 in China used the FilmArray Respiratory Panel for 74 in-patients with CAP.  
In parallel, the authors performed (i) multiplex PCR for the same 14 viruses as sought by the FilmArray 
panel, (ii) bacterial/fungal cultures by Vitek and (iii) IgM tests for C. pneumoniae and M. pneumoniae.  
Agreement between the FilmArray and multiplex PCR was complete for coronaviruses (the study pre-
dates COVID-19, which was not included), human metapneumovirus, influenza A and B and 
parainfluenza viruses. However, the FilmArray panel has fewer bacterial targets, meaning that 25 
positive bacterial cultures identified by conventional culture could not be matched to its results. Last, 
Sails et al. 55 compared the Luminex NxTAG Respiratory Pathogen Panel to an in-house multiplex real-
time PCR panel for the detection of respiratory viruses, using 314 samples (122 nasopharyngeal 
secretions, 53 throat swabs, 47 endotracheal secretions, 41 combined nose and throat swabs, 24 
sputa, 17 BALs, and 10 others) from symptomatic respiratory tract infections. Agreement was 96.2 % 
for enterovirus/rhinovirus, and 100 % for influenza A and B. 
   
BROAD-SPECTRUM TESTS TO INFORM ANTIBIOTIC USE   
The systems outlined above predominantly or solely seek viruses and atypical agents of pneumonia. 
Their potential to improve stewardship lies in discouraging unnecessary antibiotic use in patients 
found to have viral infections.  No insight is gleaned as to which antibiotic should be used when a virus 
is not found and a bacterial infection is inferred.  Moreover, such inference may or may not be correct: 
the clinical diagnosis of pneumonia is often uncertain and patients are misdiagnosed, leading to 
unnecessary use of broad-spectrum antibiotics. 56   
To address this aspect, diagnostics that seek the common bacterial agents of CAP, HAP and 
VAP have been launched recently, or are in advanced development.  Relevant PCR-based systems, all 
using respiratory secretions without culture, include the BioFire FilmArray, used with the Pneumonia 
Panel rather than the virus-directed Respiratory Panel discussed above, Seegene’s respiratory test 
with 7 bacterial targets, and the Curetis Unyvero P50/P55 and Lower Respiratory Tract Panels (Table 
3).  The most comprehensively evaluated of these are the BioFire FilmArray, used with the Pneumonia 
Panel, and the Curetis Unyvero, used with any of the three panels detailed in Table 3.  These have 
similar total numbers of targets and a near total overlap in respect of the bacterial species sought, 
including the common agents of CAP, HAP and VAP, but differ in that the BioFire FilmArray seeks a 
wide range of viruses whereas the Curetis Unyvero has more antibiotic resistance genes, including 
blaTEM, blaSHV (penicillinase/ESBL gene) and erm (macrolide resistance) determinants (Table 3).   
Turnaround for the Unyvero is around 4-5h; that for the FilmArray is shorter at a little over 1h. Both 
the manufacturers and independent researchers have carried out assessments of sensitivity and 
specificity in terms of pathogen detection (Table 4).   
As an alternative approach, Accelerate’s Pneumonia Test 57, which is in development following 
the successful launch of a  similar system testing bacteria recovered from blood 58, instead uses rapid 
phenotypic testing, employing an automated microscope to analyze the early growth of antibiotic-
challenged bacteria recovered from the sample and thereby predicting their susceptibility. In parallel, 
it uses automated fluorescence in situ hybridization technology to identify the pathogens present.  
This gives a total turnaround of 8-12 h 57, which narrowly missed our target of ‘results within the first 
dosage interval of a typical thrice-daily antibiotic’ but remains rapid compared with conventional 
methodology.   Moreover, this approach also has some advantages over PCR.  First, it seeks all bacteria 
that can grow, not just those represented on a PCR panel.  Secondly, it delivers results as minimum 
inhibitory concentrations, which can be related to pharmacodynamics, guiding antibiotic dosage, 
rather than detecting the genetic signatures of organisms that may no longer be viable, or mechanisms 
that may not be expressed.   Finally, it seeks all resistances, irrespective of underlying mechanism, not 
just the few resistance determinants (Table 3) targeted by the PCR systems.  This is potentially valuable 
in cases (see Table 1) where the molecular bases of resistance are diverse, multifactorial, or due to 
mutations that cannot readily be sought by simple PCR.
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Review of Table 4 shows considerable trial-to-trial variation in the reported sensitivity and 
specificity for both the Curetis Unyvero and BioFire FilmArray PCR systems. This divergence may partly 
reflect the types of specimens used – BALs are more likely to contain a single organism from within 
the deep lung whereas sputa are prone to more or less substantial contamination by colonizing 
bacteria from the upper airways.  In large part, though, we believe that the major issue lies in 
variability in routine bacteriological culture, which is taken as the reference ‘Gold Standard’ for the 
evaluations summarized in the table.  Unfortunately, as noted already, routine culture is far from 
perfect.  Many pneumonia patients do not have a pathogen grown, perhaps because an antibiotic was 
given before the respiratory specimen was taken, interfering with recovery in microbiological culture. 
This leads to ‘false positive’ results when the PCR system is scored against culture, reducing calculated 
specificity.  Second, and more difficult to measure objectively, is the degree of subjectivity in the 
reading of conventional respiratory cultures. Essentially the microbiologist makes a judgement on 
what is grown, and may discount small numbers of potentially pathogenic organisms, especially if 
these are heavily mixed with normal upper-respiratory-tract flora.  We believe that microbiologists’ 
reading of these plates is highly variable, basing this conclusion on results from the INHALE study 66 
presented at ECCMID 2019 and now being prepared for publication.65  We made two critical 
observations. First, when the Curetis Unyvero, BioFire FilmArray and 16S rDNA analysis were all 
applied in parallel to the same respiratory samples, their findings tended to agree, with different 
molecular systems finding the same organism(s) even when these were not grown by the diagnostic 
laboratory. Evidently, it is implausible that different molecular systems would find the same organism 
unless it was actually present, meaning that it is unreasonable (and prejudicial) to call these ‘false 
positives’.  Secondly, when we compared the results of centrally-performed molecular test to locally-
performed culture results, from the 15 participating sites, we found that the ratio of PCR positive: 
culture positive varied from 29% to 87%.  The likeliest explanation of such variation are site-to-site 
differences in the execution or interpretation of the routine microbiology.  We consequently believe 
that these molecular systems are not only swifter than conventional microbiology but also deliver a 
standardization that is presently absent.  However, it is arguable whether their finding more organisms 
than culture is advantageous or not: it can be countered that this will promote polypharmacy, some 
of it directed against organisms that were of little or no significance, or those that were already dead 
but had left their genetic signatures in the respiratory secretions.  
Several trials have explored the impact, or potential impact, of these PCR systems on patient 
outcomes.  Gastli et al. 67 performed a prospective cohort study on four wards, using the FilmArray 
Pneumonia panel on endotracheal aspirates or induced sputa from 63 pneumonia episodes among 61 
patients, concluding that the test results could have led to an early switch of antibiotics in 79% of these 
episodes.  Similarly, Lejeune et al. 68 analyzed  60 samples (30 BAL, 21 mini-BAL, 5 sputa and 4 tracheal 
aspirates), again using the FilmArray Pneumonia Panel, and estimating that the approach could have 
led to an  earlier change in antibiotics in 53% of patients.   Whilst these authors point to scope for 
better stewardship, neither demonstrated that the gain was realized in actuality.  The INHALE study 66 
seeks to explore these aspects with a trial across 12 UK ICUs. HAP/VAP patients are randomized to 
receive antimicrobial chemotherapy guided either by standard policy (empirical treatment followed 
by culture-based refinement) or the FilmArray Pneumonia Plus Panel result and an algorithm 
encourage use of the narrowest-spectrum agents to cover the pathogens and resistances found 
(shown in simplified form in Fig 2).66  Final results are anticipated in 2021. In this context, we stress 
that such a prescribing algorithm is essential to translate the machine’s output, of pathogens and 
resistance genes found, into prescribing guidance. For INHALE this algorithm was developed in liaison 
with microbiology and intensive care at participating sites, allowing some site-to-site variation (e.g. 
because pediatric sites are included and some favored agents lack pediatric licenses), retaining the 
core principle of preferring the narrowest spectrum agent to cover the pathogen(s) found.  In the 
future, if rapid testing becomes the norm, we envisage such algorithms replacing hospitals’ empirical 
treatment guidelines for clinical syndromes such as HAP and VAP.  

A general limitation of PCR systems is that they can only detect targets for which they have 
PCR primers.  Whilst the organisms represented on the Curetis Lower Respiratory Tract (Pneumonia) 
Panel and BioFire FilmArray Pneumonia Panel (Table 3) cause around 90-95% of pneumonia cases,14 
it would be difficult  - owing to limitations on the number of primers that can be multiplexed - to 
expand this proportion to 99%.  S. maltophilia is a notable omission from the FilmArray Pneumonia 
Panel, accounting for around 1-6% of VAP cases 69, 70, whilst Citrobacter koseri and Raoultella spp. are 
absent from both FilmArray and Curetis Unyvero.  Issues of omission are far greater in respect of 
resistance genes. FilmArray seeks only the determinants of various carbapenemases (blaKPC, blaOXA-48-
like, blaNDM, blaIMP, blaVIM), along with mecA (conferring methicillin resistance in staphylococci) and blaCTX-
M (encoding the principal family of extended-spectrum -lactamases, ESBLs) (Table 3).  The 
carbapenemases sought are significant both in respect of infection control and treatment choice, but 
remain extremely rare in many countries, being present in <1% of Enterobacterales from HAP and VAP 
in the UK for example.71 CTX-M ESBLs (encoded by blaCTX-M) and methicillin resistance in S. aureus 
(encoded by mecA) are more prevalent worldwide, and have implications for treatment choice; 
however only 50-70% of ESBLs in Klebsiella spp. are CTX-M types (most of the others are TEM and SHV 
variants), meaning that a negative result does not exclude the possibility that an isolate has an ESBL.  
The Curetis Unyvero seeks more resistance genes (Table 3), including blaTEM and blaSHV, encoding TEM 
and SHV -lactamases respectively, but does not distinguish whether the genes detected encode ESBL 
or penicillinase variants within these families. Moreover, blaTEM and some of the other genes sought 
(e.g. erm, encoding macrolide, lincosamides streptogramin B resistance) are common in respiratory 
commensals 72, meaning that it is difficult to be sure that the determinant ‘belongs’ to the pathogen 
found.   
Given (i) the great diversity of acquired resistance genes that are important for many 
combinations of antibiotic and species (Table 1); (ii) the importance of  diverse mutational resistances 
(which are inherently difficult to detect by PCR) in some species, notably P. aeruginosa (Table 1) and 
(iii) the fact that the resistance e.g. to -lactam--lactamase inhibitor combinations can depend on 
the  amount of -lactamase, rather than the simple presence of a -lactamase gene 73 it is difficult to 
see how these PCR systems will ever be able give a comprehensive prediction of the antibiogram(s) of 
the organism(s) found.  Rather, as with PCR-based detection of gonococci from urines and genital 
swabs, it will remain necessary for culture to be performed in parallel, in the hope of growing the 
organism(s) detected and confirming its susceptibility.  Local resistance surveillance programs will also 
be needed to inform treatment choices during the interval when the pathogen(s) have been identified 
but their susceptibility remains uncertain.   These points should not, however, detract from the fact 
that swift detection of key carbapenemase genes, in particular, will likely prove very useful in countries 
where these are widespread.  Moreover, swift determination of the particular carbapenemase type 
will guide choices among the various new -lactamase inhibitor combinations now reaching the 
clinic.74 
Brief mention should also be made of a few studies that have explored PCR to seek specific 
pathogens in respiratory secretions, and of urinary antigen testing.  Coppens et al. sought to detect S. 
aureus in 79 ETAs 75, using the GeneXpert MRSA/SA ETA assay (Cepheid) a PCR system designed for 
use with sputum samples.  They found that the method was 100% sensitive and specific compared 
with routine culture, was easy to use, and had a turnaround time of approximately 1h.  Urinary antigen 
testing is often used for the rapid detection of pneumococcal and L. pneumophila.  Notably, the IDSA 
recommends pneumococcal urinary antigen testing specifically to promote antimicrobial stewardship, 
since confirmation of pneumococcal infection often facilitates narrow-spectrum treatment. A recent 
American study emphasized this point and noted that the test was not being used as often as it could 
be.76  A retrospective Belgian multicenter study reviewed urinary antigen tests for 71 patients who 
had L. pneumophila detected by PCR of respiratory samples 77; urinary antigen tests had been 
requested for 45 of these 71, and 44.4% (20/45) of these were negative.   
 
 
SEQUENCING DIRECTLY FROM RESPIRATORY SAMPLES  
The fundamental limitation of PCR methods – that they seek only a limited range of pathogens and a 
few resistance genes – can be addressed by metagenomic sequencing directly from respiratory 
samples.  Unlike PCR, sequencing is comprehensive, with the potential to find all species, genes and 
gene variants. Several workers have shown this approach to be practicable, including Yang et al. 78 
and Charalampous et al. 72, both using nanopore technology, also and Langelier et al. 79, using 
metagenomic next-generation sequencing (NGS), combining both RNA-seq and DNA-seq.  Even more 
than with PCR, sample quality is important, since metagemonic sequencing will detect any DNA 
(bacterial or human) in a sample.  A ‘clean’ sample such as BAL may be preferred to minimize the 
amount of human DNA;  on the other hand, some workers prefer ETAs and sputa to BALs, as they 
have higher bacterial loads.   If ETAs and sputa are used, a timely and cost-effective host-DNA-
depletion step becomes vital; moreover, such samples are likely to contain more oral and upper 
respiratory tract flora, complicating interpretation.  
According to the technology used, DNA sequencing can produce long or short reads. 
Although long-read sequencing, as with nanopore technology, does not yet have the read accuracy 
of short-read technologies, e.g. Illumina, it has key advantages, providing analyzable sequence data 
in real-time, helping to establish which organisms are hosting resistance genes, and permitting 
easier genome assembly. These advantage are crucial for the development of rapid/POCT 
diagnostics.   
Li et al., 80 in China, used short-read metagenomic sequencing on 35 BAL samples from 32 
ICU patients with respiratory failure.  DNA was extracted using the TIANamp Micro DNA Kit, and 
libraries were sequenced on the BGISEQ-50 platform with the Burrows-Wheeler Alignment tool. 81  
Pathogen read numbers were low, partly reflecting the lack of a host DNA depletion step, and with 
most positive results were based on < 50 reads/organism detected.  Despite these limitations, the 
method achieved a sensitivity of 88.9% and a specificity of 74.1% compared with routine culture in 
terms of species identification.  The authors commented that, for approximately a third of their 
cohort, the metagenomic NGS led to a change in treatment. The time to result is not stated, nor is 
the range of genome coverage, and no information is given on the resistance genes found – it seems 
likely that the approach gave too few reads for reliable detection of resistance genes.  Two other 
studies using Illumina sequencing deserve mention.  In Japan, Takeuchi et al., 82 investigated 10 
pediatric patients with respiratory failure, and a Lopez et al. in Spain, investigated 55 chronic 
obstructive pulmonary disease (COPD) patients 83; both concluded that metagenomic sequencing 
was useful for pathogen detection.   
Nanopore sequencing, with advantages of speed and long-reads, was first explored for 
respiratory samples by Charalampous et al. 72 in the UK, with a novel saponin-based host DNA 
depletion method.  They achieved a 6-h turn-around time, including host-DNA depletion, and found 
96.6% sensitivity and 41.7% specificity compared with culture.  Both these values increased to 100% 
following PCR verification of discordant results and post-hoc specific gene analysis for all H. 
influenzae- and/or S. pneumoniae-positive samples.  Resistance genes were found but often without 
an obvious host being recognized by sequencing or culture.  In particular, the authors often found 
tet, erm and blaTEM determinants when the only pathogen(s) grown remained susceptible to 
tetracyclines, macrolides or -lactams, or were organisms inherently unlikely to host these genes. It 
was inferred that these genes originated in the commensal flora, not the pathogens, and the scope 
for uncertainty, if the method was deployed clinically, is evident.    Bioinformatic analysis of the DNA 
flanking resistance genes, might resolve this aspect when resistance genes are chromosomally 
located, but is less likely to be useful when they are plasmid-borne, since the plasmid’s host would 
remain uncertain.  A further issue remains when, as in P. aeruginosa, resistance is commonly 
effected by combinations of mechanisms (e.g. upregulation of efflux pumps and increased 
expression of AmpC -lactamase) (Table 1) with these up-regulations arising from diverse mutations 
in any of several regulatory genes. Almost all P. aeruginosa isolates have some functioning efflux via 
MexA-MexB-OprM:  what matters is the extent to which this system is expressed as a result of 
regulatory mutations in mexR 84, or is augmented by upregulation of multiple further pumps.85  A 
possible solution is ‘genomic neighbor typing’ – a method that matches genome sequences from the 
clinical sample to a database of sequences and susceptibility data from known variants, to find the 
closest match.  Brinda et al. 86 used this approach with nanopore sequence data for S. pneumoniae 
and Neisseria gonorrhoeae – both organisms where resistance to -lactams depends on complex 
mixtures of mutation and gene recombination, achieving good prediction of susceptibility and 
resistance within 4 h of sample collection.  Future work may allow this bioinformatic strategy to be 
expanded to other ‘difficult’ organisms, including P. aeruginosa; nonetheless, these aspects 
underscore the complexity of the metagenomic pipelines that will be needed to translate sequence 
data into prescribing decisions.  More generally, although the broad steps involved in sequencing are 
identical across methods, every metagenomic pipeline is different.  Consequently, no uniform 
algorithm to interpret results in likely to be possible.  Nevertheless, key themes will be universal, 
such as the threshold number of reads considered significant, and controlling for contamination.     
    Yang et al. 78 in the USA, used the Oxford MinION nanopore device with endotracheal 
aspirates from 9 patients with culture-positive pneumonia, 5 with culture-negative pneumonia and 
from 8 controls.  Results were compared with both bacteriological cultures and 16S rRNA gene 
sequencing, and the team reported excellent concordance between the nanopore and both culture 
and 16S rRNA results.  Nanopore sequencing and data analyses were not performed in real-time 
because of a retrospective study design, however a turn-around time of 6-8 h was achieved including 
host DNA depletion, with good pathogen genome coverage and detection of antimicrobial resistance 
genes.  Notably, the authors detected organisms (S. aureus, H. influenzae or S. pneumoniae) that can 
be either pathogens or commensals (‘pathobionts’) in patients with no evidence of pneumonia, 
highlighting the need for caution in interpreting results. 
Advances in rapid host-DNA depletion and in bioinformatics make it likely that 
metagenomics will become the future for the rapid microbiological investigation of respiratory tract 
infections, with far greater comprehensiveness than PCR.   As yet, however, these methods require 
substantial technical skill, and are not yet ready for routine use.  A further issue is cost, which is 
likely to be in the low hundreds of dollars per sample – expensive compared with culture though not 
when compared with an extra day’s stay in the ICU. 
 
THE PRACTICALITIES OF INTRODUCING MOLECULAR METHODS  
Our analysis, like that of others 87, 88, indicates that molecular methods – particularly PCR and, in the 
future, metagenomic sequencing – have considerable potential for the better investigation of 
pneumonia, increasing diagnostic yield and providing early treatment guidance.  Nonetheless, great 
challenges remain. Some are technical and have been discussed already; others relate to the 
practicalities and logistics of deployment.  
First there is the question of where tests will be done.  If the answer is ‘In the laboratory, 
where else?’ then it is likely that transport to the laboratory, ‘booking in’ and possible batch processing 
will take longer than the tests themselves, partly negating the advantage of test speed.  This issue will 
be exacerbated if the laboratory is physically separate from the hospital and does not work ‘24/7’.  
The potentials of rapid tests run counter to the recent trend - predicated on objectives of 
standardization, quality control and cost minimization - to centralize laboratories and to have them 
serve multiple hospitals.  A recent review by Vandenberg et al 89 discusses this issue in greater detail.    
Retaining a small ‘hot’ laboratory at every hospital for urgent tests would resolve this issue, but would 
add significant cost, over and above that of the tests themselves.  
If, instead, POCTs are performed by the patient’s bedside, not in a laboratory, then ward staff 
will need to be trained to use them, meaning that the tests must not require specialist laboratory 
expertise, and that their results and interpretation cannot be operator dependent. Alternatively, 
communication systems must facilitate swift microbiology, infectious disease and infection control 
advice on a 24/7 basis.  Quality control also needs to be considered, as ward-based POCTs would no 
longer be under the remit of laboratory accreditation.  Further factors to consider are machine 
maintenance and interfacing with hospital computer systems.  Crucial to test interpretation is the 
issue of distinguishing colonist and pathogens, as highlighted in a Swiss study that tested 35 diagnostic 
BAL specimens using a rapid broad-range PCR and microarray-based nucleic acid amplification test 
called Prove-it Sepsis Assay.90  The authors concluded that the clinical relevance of the results was 
uncertain, and that colonizing organisms may be difficult to differentiate from pathogens.  This 
underscores the point, made earlier, that PCR-based diagnostics tend to find more positives than 
culture, giving credence to DNA from small numbers of organisms that might have been discounted 
by a skeptical Biomedical Scientist reading culture plates. This issue is partly addressed on newer 
commercial platforms, including the Unyvero and FilmArray, where results are semi-quantitative 
giving an indication of the number of gene copies and bacterial load.  If this is high, infection is inferred 
to be more likely.   
Secondly, and linked to this first point, is the issue of where rapid tests best fit into hospital 
and community care pathways.  Should they be used to decide when to stop/ start antibiotics? When 
to admit patients presenting at A&E? Which settings would benefit most from POCTs: ICU, A&E or 
community care?  Answers may vary according to the hospital and the health system.  
Thirdly, there is the question of costs – molecular tests are considerably more expensive than 
bacterial culture, costing anywhere from $60-400 vs. c. $12-25. A comprehensive health economic 
analysis is required to establish whether swifter refinement of patients’ treatment translates into cost 
savings. Moreover, unless they are comprehensive – which is unlikely, except for sequencing-based 
systems and rapid phenotypic systems – rapid tests for pathogens and resistances will be in addition 
to conventional testing, not a replacement.  Whilst gains in stewardship and patient management may 
recoup some additional costs, savings accrue remotely from the cost center for the test, complicating 
accounting.  Moreover, efficiency gains are notoriously difficult to translate into cash savings in 
socialized healthcare, such as the UK NHS, operating at near-full capacity.  A patient may be discharged 
earlier, giving a notional ‘saving,’ but their bed is immediately filled by a new patient, whose new costs 
are likely to exceed those of an extra day’s stay by the original patient. Cost savings may be more 
obviously realizable in settings where the patient, or their insurer, pays directly. 
Last, and most subtle: behavioral aspects are crucial, and are apt to vary with place and human 
culture.  ICU decisions relating to antibiotic prescribing in particular are multifactorial and complex, as 
outlined in systematic reviews by Warreman et al. and Krockow et al.91, 92  Key factors include fear of 
adverse outcomes and the experience of clinician.  Adding molecular tests that detect more organisms 
and resistance genes than culture may prompt more polypharmacy rather than better stewardship. It 
is unclear, as yet, how much clinicians will trust these tests and how this will change if the test machine 
sits in the ICU rather than remotely in the laboratory.  The INHALE trial, outlined earlier, aims to 
explore these aspects: behavioral psychologists will investigate decision making among ICU clinicians 
in relation to both the FilmArray and routine culture results, identifying key intervention points to 
optimize stewardship. Again, the likely solution will lie in different ways of working for microbiologists, 
who will need to provide urgent advice on test interpretation, rather than running tests in their ‘own’ 
laboratories. 
       
CONCLUSION – TAKING DEPLOYMENT FORWARDS 
This review has outlined the potentials, in respect of antimicrobial stewardship, of the various rapid 
diagnostics relevant to for pneumonia, including (i) those that examine human biomarkers as 
predictors of infection type, (ii) those – already widely used – that seek respiratory viruses, and (iii) 
those, now reaching the market, that use PCR or rapid phenotypic testing to seek ranges of bacterial 
pathogens and antibiotic resistance genes.  Sequencing-based tests are for the future, but have 
potential to be far more comprehensive than PCR, particularly in respect of predicting resistance.  It 
is likely, that no single approach will be overwhelmingly successful but that, collectively, these 
approaches will facilitate a major shift in the management of respiratory infection.   
Although POCTs have greatest potential as bedside tools, their use for pneumonia patients 
will need strong microbiology and/or infectious disease advice if their often-complex findings are to 
be best-translated into treatment advice and antimicrobial stewardship.  Perhaps the biggest barriers 
to change and progress are people and tradition; deployment of these tests will demand significant 
changes to ways of working both in the clinic and in microbiology department.    In closing, it should 
be added that COVID-19 – unknown when this review was first drafted, but pandemic and massively 
disruptive worldwide by the time of its publication – seems certain to drive major changes in hospital 
practice.  In the short term the emphasis will be on detecting SARS-CoV2 specifically; in the longer 
term, depending on how the pandemic evolves, the virus may prover a driver to much wider changes 
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